Puma Biotechnology (PBYI)

Executive Summary

Puma Biotechnology is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. Its lead product, Nerlynx (neratinib), an oral tyrosine kinase inhibitor, is approved for HER2-positive breast cancer. The company is also advancing alisertib, an Aurora A kinase inhibitor, in clinical trials. Financially, Puma generates recurring revenue from Nerlynx sales, but faces competition from other HER2-directed therapies. The pipeline includes several Phase 2 studies evaluating neratinib in combination therapies for various breast cancer subtypes, and a Phase 2 trial of alisertib plus paclitaxel in small cell lung cancer (SCLC) initiated in 2026. With a market cap around $380 million, Puma's near-term value hinges on clinical data readouts and potential label expansions. The company's focused pipeline and existing commercial product provide a foundation, though limited pipeline breadth and competitive pressures temper conviction.

Upcoming Catalysts (preview)

• 2028Alisertib Phase 2 Data in SCLC40% success
• 2027Neratinib Combination Trial Results in HR+/HER2+ Breast Cancer60% success
• 2026 H2Potential FDA Approval for Neratinib Label Expansion in Early-Stage Breast Cancer35% success